| 1.68 -0.46 (-21.5%) | 10-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.87  |
1-year : | 5.12 |
| Resists | First : | 3.32 |
Second : | 4.38 |
| Pivot price | 2.54 |
|||
| Supports | First : | 1.59 |
Second : | 1.32 |
| MAs | MA(5) : | 2.12 |
MA(20) : | 2.45 |
| MA(100) : | 8.74 |
MA(250) : | 25.16 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.5  |
| %K %D | K(14,3) : | 4 |
D(3) : | 5.2 |
| RSI | RSI(14): 31.3 |
|||
| 52-week | High : | 76.5 | Low : | 1.59 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VBIO ] has closed below the lower bollinger band by 3.2%. Bollinger Bands are 69.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 29 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.14 - 2.16 | 2.16 - 2.17 |
| Low: | 1.56 - 1.57 | 1.57 - 1.59 |
| Close: | 1.66 - 1.68 | 1.68 - 1.7 |
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Sat, 10 Oct 2026
Valion Bio, Inc. (VBIO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Fri, 09 Oct 2026
Valion completes oral Entolimod formulation work - grafa.com
Fri, 09 Oct 2026
A potential radiation drug could be absorbed through the mouth instead of injected. - Stock Titan
Fri, 09 Oct 2026
Valion Bio Secures Additional Series B Preferred Financing - The Globe and Mail
Thu, 08 Oct 2026
Valion Bio Raises $50,000 in Private Sale of Series B Preferred and Warrants to 3i - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 879580 (%) |
| Held by Institutions | 0.6 (%) |
| Shares Short | 340 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.654e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 19 % |
| Return on Assets (ttm) | 652.3 % |
| Return on Equity (ttm) | -57.2 % |
| Qtrly Rev. Growth | -86000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -255.29 |
| EBITDA (p.s.) | -30000 |
| Qtrly Earnings Growth | -178 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.11 |
| Dividend | 0 |
| Forward Dividend | 87970 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|